# Scenario 001 Final Pre-Review Report

## Review Summary

This is a deterministic pre-review report for `scenario_001`. It reviews a synthetic early protocol outline for Type 2 diabetes mellitus and GLP-1 receptor agonist add-on therapy.

This report is for planning and expert review preparation only. It does not approve the protocol, certify regulatory compliance, make patient-specific recommendations, or use real patient data.

## Protocol Completeness Checklist

- disease_condition: present
- intervention_or_drug_class: present
- trial_phase: present
- trial_objective: present
- target_population: present
- draft_inclusion_criteria: present
- draft_exclusion_criteria: present
- primary_endpoint: present
- secondary_endpoints: present
- expected_data_collection_items: present

## Similar-Trial / Evidence Items To Check

- Live retrieval performed: True
- Retrieval status: success
- Query count: 5
- Retrieved records: 21
- Baseline query URL: `https://clinicaltrials.gov/api/v2/studies?format=json&pageSize=5&query.cond=Type+2+diabetes+mellitus&query.intr=GLP-1+receptor+agonist`

Ranked source candidates:

| Rank | NCT ID | Score | Relevance | Phase | Key Reason |
| ---: | --- | ---: | --- | --- | --- |
| 1 | `NCT01596504` | 9/10 | high | PHASE2 | direct GLP-1 receptor agonist or representative drug match |
| 2 | `NCT05067621` | 9/10 | high | PHASE2 | direct GLP-1 receptor agonist or representative drug match |
| 3 | `NCT01117350` | 9/10 | high | PHASE4 | direct GLP-1 receptor agonist or representative drug match |
| 4 | `NCT01373450` | 9/10 | high | PHASE1 | direct GLP-1 receptor agonist or representative drug match |
| 5 | `NCT02449603` | 9/10 | high | PHASE4 | direct GLP-1 receptor agonist or representative drug match |

Top-trial comparison file:

- `prototype/runs/scenario_001_run_001/top_trial_comparison.md`
- `prototype/runs/scenario_001_run_001/top_trial_interpretation_notes.md`
- `prototype/runs/scenario_001_run_001/medical_plausibility_safety_review.md`

Retrieved study summaries:

- `NCT00630825`: A Study of Dose Titration of LY2189265 in Overweight Participants With Type 2 Diabetes Mellitus
  - status: COMPLETED
  - phase: PHASE2
  - interventions: LY2189265, Placebo
  - primary outcomes: Change From Baseline in Glycosylated Hemoglobin (HbA1c) in Overweight and Obese Participants With Type 2 Diabetes Mellitus
- `NCT01117350`: Efficacy Assessment of Insulin Glargine Versus LiraglutidE After Oral Agents Failure
  - status: COMPLETED
  - phase: PHASE4
  - interventions: Insulin glargine, Liraglutide, Metformin
  - primary outcomes: Percentage of Patients Whose Glycosylated Haemoglobin (HbA1c) <7% at the End of the Comparative Period
- `NCT01373450`: Evaluation of the Glucoregulatory Effects of Glucagon-like Peptide-1 Receptor (GLP-1 Receptor) Activation in Participants With Type 2 Diabetes Mellitus (MK-0000-222)
  - status: COMPLETED
  - phase: PHASE1
  - interventions: Oxyntomodulin, Liraglutide 0.6 mg, Liraglutide 1.2 mg, Placebo for Oxyntomodulin, Placebo for Liraglutide
  - primary outcomes: Change From Baseline in Time-weighted Average of Glucose Measured by Area Under the Curve (AUC) After a Single Dose of Oxyntomodulin (OXM), Change From Baseline in Maximum Ambient Glucose Concentration (Gmax) After a Single Dose of OXM, Change From Baseline in Beta Cell Sensitivity to Glucose (Φ) After a Single Dose of OXM
- `NCT01542242`: Liraglutide Use in Prader-Willi Syndrome
  - status: TERMINATED
  - phase: PHASE4
  - interventions: Liraglutide
  - primary outcomes: Hemoglobin A1C
- `NCT01596504`: Pharmacodynamic Effects of Lixisenatide Compared to Liraglutide in Patients With Type 2 Diabetes Not Adequately Controlled With Insulin Glargine With or Without Metformin
  - status: COMPLETED
  - phase: PHASE2
  - interventions: Lixisenatide (AVE0010), Liraglutide, Insulin Glargine, Metformin
  - primary outcomes: Change From Baseline to Day 56 in Plasma Glucose Corrected Area Under The Plasma Concentration-Time Curve (AUC) From Time 0.5 Hours to 4.5 Hours
- `NCT01876849`: An Open-Label Study Examining the Long-Term Safety of Exenatide Given Twice Daily to Patients With Type 2 Diabetes Mellitus
  - status: COMPLETED
  - phase: PHASE3
  - interventions: exenatide
  - primary outcomes: Long-term safety of twice-daily exenatide treatment, as defined by the occurrence of adverse events.
- `NCT02274740`: Effect of Lixisenatide on Postprandial Lipid Profile in Obese Type 2 Diabetic Patients
  - status: TERMINATED
  - phase: PHASE2
  - interventions: LIXISENATIDE AVE0010, metformin
  - primary outcomes: Change in plasma triglycerides after 10 weeks of treatment area under-the-time concentration curve between 0 and 480 minutes (AUC0-480 min)
- `NCT02449603`: Comparison of Exenatide vs. Biphasic Insulin Aspart 30 on Glucose Variability in Type 2 Diabetes
  - status: COMPLETED
  - phase: PHASE4
  - interventions: Exenatide, Biphasic insulin Aspart 30
  - primary outcomes: Change of mean amplitude of glycemic excursions
- `NCT02981069`: Effect of Chronic Exenatide Therapy on Beta Cell Function and Insulin Sensitivity in T2DM
  - status: COMPLETED
  - phase: PHASE4
  - interventions: Dapagliflozin, Exenatide, Placebo
  - primary outcomes: Change in Endogenous Glucose Production (EGP) After Acute Exposure to a Single Dose and Again After 16 Weeks of Treatment, Change in Endogenous Glucose Production (EGP) After 16 Weeks of Treatment With Each Study Drug.
- `NCT03015220`: Safety and Efficacy of Oral Semaglutide Versus Dulaglutide Both in Combination With One OAD (Oral Antidiabetic Drug) in Japanese Subjects With Type 2 Diabetes
  - status: COMPLETED
  - phase: PHASE3
  - interventions: Semaglutide, Dulaglutide
  - primary outcomes: Number of Treatment-emergent Adverse Events (TEAEs)
- `NCT03648554`: Researching an Effect of GLP-1 Agonist on Liver STeatosis (REALIST)
  - status: UNKNOWN
  - phase: PHASE4
  - interventions: dulaglutide (TRULICITY®) 1.5 mg, reinforced dietary monitoring
  - primary outcomes: Responder's proportion difference between the two groups (dulaglutide (TRULICITY®) on top of dietary reinforcement vs. dietary reinforcement alone)
- `NCT04513704`: A Clinical Trial Comparing Semaglutide in Healthy People Who Eat and Take the Medicine at Different Times
  - status: COMPLETED
  - phase: PHASE1
  - interventions: Oral Semaglutide
  - primary outcomes: Area under the semaglutide plasma concentration - time curve during a dosing interval after the 10th dosing (AUC0-24h,sema,day10)
- `NCT05005741`: The Effects of Glucose Control and Weight Loss Between Beinaglutide and Dulaglutide in Type 2 Diabetes With Overweight or Obesity.
  - status: UNKNOWN
  - phase: PHASE4
  - interventions: Beinaglutide, Dulaglutide
  - primary outcomes: haemoglobin A1c(HbA1c)
- `NCT05067621`: Semaglutide Effects in Obese Youth With Prediabetes/New Onset Type 2 Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease
  - status: ACTIVE_NOT_RECRUITING
  - phase: PHASE2
  - interventions: Semaglutide Pen Injector, Placebo
  - primary outcomes: Change in Oral Disposition Index (oDI), Change in Protein Density Fat Fraction (PDFF)
- `NCT05073692`: Comparison of Type 2 Diabetes Pharmacotherapy Regimens
  - status: COMPLETED
  - phase: not listed
  - interventions: SU, DPP4, SGLT2i, GLP-1RA, SGLT2i or GLP-1RA
  - primary outcomes: Incidence of 3-point Major Adverse Cardiovascular Events (MACE)
- `NCT05407961`: A Study of LY3532226 in Participants With Type 2 Diabetes Mellitus
  - status: COMPLETED
  - phase: PHASE1
  - interventions: LY3532226, Placebo, Dulaglutide
  - primary outcomes: Part A: Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration, Part B: Change from Baseline in Total Clamp Disposition Index (cDI)
- `NCT05473286`: A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Germany, as Part of Local Clinical Practice
  - status: WITHDRAWN
  - phase: not listed
  - interventions: Oral Semaglutide
  - primary outcomes: Change in Glycated haemoglobin (HbA1c )
- `NCT06182852`: The Effect of GLP-1 Receptor Agonist on Bone Metabolism in Patients With Diabetes Mellitus
  - status: UNKNOWN
  - phase: not listed
  - interventions: not listed in extracted fields
  - primary outcomes: Bone metabolism, Bone mineral density, HbA1c
- `NCT06247748`: Influence of JY09 on Pharmacokinetics of Metformin , Rosuvastatin , and Digoxin and the QT Interval Study in Overweight Chinese Subjects
  - status: COMPLETED
  - phase: PHASE1
  - interventions: Exendin-4 Fc fusion protein (JY09) injection, Metformin Hydrochloride tablet, Rosuvastatin calcium tablets, Digoxin tablet
  - primary outcomes: The Metformin Peak Concentration (Cmax ), Area under the Metformin blood concentration-time curve, The Rosuvastatin Peak Concentration (Cmax )
- `NCT06706284`: Glycemic and Weight Loss Effects of GLP-1R Agonist Therapy in Subjects With Spinal Cord Injury and Type 2 Diabetes
  - status: RECRUITING
  - phase: PHASE4
  - interventions: Semaglutide Injectable Product, Placebo
  - primary outcomes: Glucose tolerance, Insulin action
- `NCT07662213`: A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes Mellitus
  - status: NOT_YET_RECRUITING
  - phase: PHASE3
  - interventions: Elecoglipron, Semaglutide
  - primary outcomes: Change from baseline in Hemoglobin A1c (HbA1c)

Fields to compare later:

- NCT ID
- brief title
- conditions
- interventions
- phase
- primary outcomes
- secondary outcomes
- eligibility criteria
- recruitment status

## Eligibility And Recruitment Flags

- **HIGH**: HbA1c eligibility threshold is ambiguous. Recommendation: Define an exact HbA1c range or threshold for eligibility.
- **HIGH**: Renal impairment exclusion criterion lacks an operational threshold. Recommendation: Define the threshold using eGFR, creatinine clearance, or another measurable criterion.
- **HIGH**: Study design, randomization, blinding, and comparator details are not specified. Recommendation: Clarify whether the study is randomized, blinded, placebo-controlled, active-comparator, or single-arm.
- **MEDIUM**: Recruitment assumption is provided without feasibility rationale. Recommendation: Add screening pool, historical recruitment rate, or site feasibility evidence.
- **MEDIUM**: Current injectable diabetes therapy exclusion may reduce the eligible recruitment pool. Recommendation: Estimate how many otherwise eligible patients would be excluded and clarify whether this criterion is clinically necessary.
- **MEDIUM**: Follow-up visit attendance criterion needs an operational definition. Recommendation: Define required visit windows, acceptable missed visits, remote visit options, and how attendance feasibility will be assessed.
- **HIGH**: Safety monitoring plan is not specified. Recommendation: Clarify adverse event review, safety labs, stopping rules if applicable, and responsible reviewers.
- **MEDIUM**: Prior GLP-1 receptor agonist exposure is not addressed in eligibility criteria. Recommendation: Clarify whether prior or recent GLP-1 receptor agonist use is allowed, excluded, or stratified.
- **MEDIUM**: Adverse events are listed as data items, but the capture workflow is unclear. Recommendation: Specify how adverse events will be captured, reviewed, coded, and reconciled.

Known user-provided concerns:

- HbA1c threshold is not specified.
- Renal impairment threshold is not specified.
- Prior GLP-1 receptor agonist exposure is not addressed.
- Recruitment assumption may be optimistic for a single center.

## Hospital Data-Readiness Notes

| Data Item | Likely Source Category | Collection Mode | Risk | Clarification Needed |
| --- | --- | --- | --- | --- |
| Demographics. | registration/demographic data | routine hospital system | low | no |
| Diabetes diagnosis history. | diagnosis/problem list | routine hospital system | medium | no |
| Medication history. | medication/order records plus manual reconciliation | mixed routine and manual | medium | yes |
| HbA1c. | laboratory results | routine hospital system or protocol-specific lab | medium | no |
| Fasting plasma glucose. | laboratory results | routine hospital system or protocol-specific lab | medium | no |
| Body weight and BMI. | vitals or clinical measurements | routine hospital system | low | no |
| Renal function laboratory results. | laboratory results | routine hospital system or protocol-specific lab | medium | no |
| Pregnancy test result where applicable. | laboratory results | routine hospital system or protocol-specific lab | medium | no |
| Informed consent documentation. | research consent documentation | research-only/manual | high | yes |
| Adverse events. | research-specific adverse event capture plus clinical notes | research-only/manual plus notes | high | yes |
| Concomitant medications. | medication/order records plus manual reconciliation | mixed routine and manual | medium | yes |
| Visit schedule and follow-up completion. | scheduling/visit records plus research tracking | mixed routine and manual | medium | yes |

Detailed data-readiness file:

- `prototype/runs/scenario_001_run_001/data_readiness_table.md`

Boundary: This mapping uses broad hospital/research data categories only and does not claim access to real EMR/HIS data.

## Missing Or Ambiguous Items

- HbA1c eligibility threshold is ambiguous.
- Renal impairment exclusion criterion lacks an operational threshold.
- Study design, randomization, blinding, and comparator details are not specified.
- Recruitment assumption is provided without feasibility rationale.
- Current injectable diabetes therapy exclusion may reduce the eligible recruitment pool.
- Follow-up visit attendance criterion needs an operational definition.
- Safety monitoring plan is not specified.
- Prior GLP-1 receptor agonist exposure is not addressed in eligibility criteria.
- Adverse events are listed as data items, but the capture workflow is unclear.

## Assumptions, Limitations, And Expert Follow-Up Questions

Assumptions:

- The scenario is synthetic and contains no real patient data.
- Hospital data availability notes are user-provided assumptions, not verified EMR/HIS evidence.
- ClinicalTrials.gov retrieval was performed with an expanded query set, de-duplicated by NCT ID, and selected public registry fields were stored in `sources.json`.

Limitations:

- This report uses local fixture data only.
- It does not validate scientific correctness.
- It does not replace PI, CRC, IRB/regulatory, sponsor, or medical data-team review.
- Retrieved ClinicalTrials.gov records are broad public registry matches and may not be Phase II-only or directly equivalent to the draft protocol.

Expert follow-up questions:

- What exact HbA1c range defines eligibility?
- What eGFR or creatinine clearance threshold defines severe renal impairment?
- Is prior GLP-1 receptor agonist use excluded or allowed?
- What is the planned study design: randomized, open-label, placebo-controlled, active comparator, or single-arm?
- How will adverse events be captured and reviewed?
- What data elements are expected from routine EMR versus research-only forms?
- What evidence supports the recruitment assumption?
